Cholinergic Urticaria: Subtype Classification and Clinical Approach

Atsushi Fukunaga1,2 · Yoshiko Oda1 · Shinya Imamura1 · Mayuko Mizuno1 · Takeshi Fukumoto1 · Ken Washio3

Accepted: 26 August 2022 / Published online: 15 September 2022 © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract
Cholinergic urticaria (CholU) is a subtype of chronic inducible urticaria with a chief complaint of itching and/or stinging, painful papular wheals that develop simultaneously with sweating. This review specifically focuses on several subtypes of CholU and specifically investigates the relationship between CholU and anhidrosis. We review recent publications and update the evidence around CholU, including the epidemiology, clinical features, diagnostic approaches, physiopathology, subtype classification, and therapeutic approaches. Multiple mechanisms contribute in a complex manner to the development of CholU, including histamine, sweat allergy, cholinergic-related substances, poral occlusion, and hypohidrosis/anhidrosis. A new schematic of the currently known pathological conditions has been created. Specific methods for diagnosing CholU, a provocation test, and evaluation methods for disease severity/activity and disease burden of CholU are summarized. The characteristics of the diseases that should be differentiated from CholU and examination methods are also summarized. The primary finding of this review is that CholU should be categorized based on the etiology and clinical characteristics of each subtype to properly manage and treat the disease. This categorization leads to improvement of therapeutic resistance status of this disease. In particular, a sweating abnormality should be given more attention when examining patients with CholU. Because CholU is not a homogeneous disease, its subtype classification is important for selection of the most suitable therapeutic method. Further elucidation of the pathophysiology of each subtype is expected.

Key Points
The etiology of cholinergic urticaria remains unclear, but it is clinically important to focus on the subtypes of cholinergic urticaria, including sweating dysfunction.
Various tests, including the thermal sweating test, are required to classify the subtypes of cholinergic urticaria.
Focusing on the subtypes of cholinergic urticaria will significantly contribute to effective therapeutic decision making.

1 Introduction
Cholinergic urticaria (CholU), first described by Duke [1] in 1924, manifests as pinpoint, highly pruritic, or often painful wheals with surrounding erythema. These wheals occur after sweating induced by an increase in the body temperature, which occurs in response to hot bathing, physical exercise, and emotional stress [2, 3]. Cholinergic urticaria is a common form of chronic inducible urticaria, which is a subgroup of chronic urticaria [a group of diseases characterized by the recurrence of itchy wheals and/or angioedema (AE) for longer than 6 weeks], and affects up to 20% of young adults [4–6]. Cholinergic urticaria is defined as inducible urticaria in the Japanese Dermatological Association guidelines for the diagnosis and treatment of urticaria [7].
2 Definition, Subtype Classification, and Pathophysiology of CholU

2.1 Definition and Clinical Characteristics

Cholinergic urticaria is characterized by itching and/or stinging pain, redness, and papular whealing, AE, or both induced by exercise and passive warming. Some patients develop symptoms of CholU when they are emotionally stressed or eat hot or spicy foods. A typical cutaneous symptom is the development of punctate short-duration (15–60 min) wheals of 1–3 mm, but these punctate wheals occasionally become larger in size and coalesce to form a large wheal (Fig. 1a). The eruptions may occur anywhere on the body except the palms, soles, and axillae, and the most commonly affected part of the body is the trunk [2, 3, 5]. Cholinergic urticaria is often associated with serious symptoms such as anaphylaxis, AE (Fig. 1b), dyspnea, and severe pain [12, 16, 17, 27]. Further investigation and discussion are needed regarding the difference between food-independent exercise-induced anaphylaxis (EIA) [28] and CholU with anaphylaxis. In many patients, symptoms of CholU become exacerbated in hot weather; some patients, however, including those who have subtypes of CholU with anhidrosis, often experience worsening in colder living environments with temperature differences.

2.2 Subtype Classification

As mentioned above, we have proposed four subtypes of CholU based on the pathogenesis and clinical features: (i) conventional sweat allergy-type CholU, (ii) follicular-type CholU with a positive autologous serum skin test (ASST) result, (iii) CholU with palpebral AE (CholU-PA), and (iv) CholU with acquired anhidrosis and/or hypohidrosis (CholU-Anhd) [10, 17, 19, 21, 23–25]. Conventional sweat allergy-type CholU and CholU with palpebral AE are characterized by type I allergy to the patient’s own sweat; thus, both can be considered sweat allergy-type CholU. Cholinergic urticaria with acquired anhidrosis and/or hypohidrosis is characterized by a reduced amount of sweat without a clear cause and can be classified as acquired idiopathic generalized anhidrosis (AIGA) accompanied by CholU [26]. Because the etiology and therapeutic approach differ greatly for each subtype, it is very important to not only consider CholU as a single disease but also conduct medical examinations with awareness of the subtypes. In the present review, we focus on the classification of CholU, especially with respect to the relationship between CholU and sweating function, and present an overview of the current knowledge of the pathogenesis and therapeutic methods of CholU.

(continued)
lack of development of satellite wheals following a local ACh injection, and a positive ASST result. Takahagi et al. [32] found that 23 of 35 patients with CholU exhibited histamine release from basophils in response to semi-purified sweat antigen, which induced histamine release from mast cells and basophils via antigen-specific IgE in patients with atopic dermatitis, in 2009. In their report, the group that tested positive for the semi-purified sweat antigen tended to have more complications involving atopic diseases such as atopic dermatitis and asthma. The group that tested positive for the semi-purified sweat antigen had a positive ASST result and a negative ASwST result [35]. From these data, it may be possible to easily infer the complication of a sweat allergy in patients with CholU by measuring Malassezia-specific IgE in patients with CholU.

2.2.2 Follicular-Type CholU

In our 2005 paper, we proposed classification of CholU into two subtypes, and follicular-type CholU is the second of these two subtypes [24]. Patients with follicular-type CholU tend to have a positive ASST result and a negative ASwST result, indicating that this subtype is not associated with a sweat allergy. We found that patients with ASST-positive CholU who have no sweat allergy were more likely to have erythematous wheals consistent with hair follicles. Therefore, this subtype of CholU was termed follicular-type CholU (Fig. 1c). The etiological involvement of autologous serum factor and ACh is unknown in this subtype. It has been suggested that serum factor and ACh may act on mast cells around the hair follicles to produce wheals that are

![Fig. 1 Diversity of clinical picture of cholinergic urticaria (CholU).](image)

- **a** Typical appearance of CholU: pinpoint-sized, highly pruritic red wheals occur after sweating.
- **b** Cholinergic urticaria with palpebral angioedema (CholU-PA): angioedema associated with cholinergic urticaria.
- **c** Follicular-type CholU: CholU matching hair follicles.
- **d** Goosebump-like punctate rash with surrounding erythematous halo
coincident with the hair follicles [19]. Furthermore, the presence or absence of anhidrosis in patients with CholU in our 2005 paper has not been considered and requires further study. How to distinguish this subtype of CholU from aquagenic urticaria, which is characterized by the formation of punctate wheals coincident with follicles, is also an important issue [36, 37].

2.2.3 CholU-PA

Exercise-induced AE without trigger foods has been reported as a rare symptom of CholU [38, 39], although the causative allergen and clinical features are not well understood. We reported the clinical features of 15 cases of CholU with AE around the eyelids and proposed this as a new subtype of CholU: CholU-PA in 2017 [17]. This characteristic subtype of CholU was closely associated by AE around the eyelids and often anaphylaxis (7/15), and it was closely related to atopic predisposition (14/15) of female sex (15/15) (Fig. 1b). All patients with CholU-PA had a positive ASwST result, whereas only four patients had a positive ASST result, indicating that all patients with CholU-PA had an allergy to autologous sweat and a low predisposition to autoimmune urticaria. Interestingly, wheals in these patients with CholU-PA often appeared in lesions with an eczematous response consistent with eyelid-related atopic dermatitis. This means that these lesions are prone to sweat leakage due to impaired sweat duct barriers within the dermis; this easily induces sensitization to sweat, and the subsequent sweat allergy induces an eczematous reaction and urticarial reaction in the lesions. In addition, Mellerowicz et al. [16] subsequently reported that CholU was frequently associated with AE (46% of patients had at least one AE episode). Among patients with CholU, higher rates of concomitant allergies (53% vs 35%) and atopic dermatitis (16% vs 5%) were seen in those with than without AE, but these differences were not statistically significant ($p = 0.053$ and $p = 0.058$, respectively). These findings are similar to the results of our previous study. Interestingly, they found that among patients with CholU, those with AE are significantly more likely to experience extracutaneous signs and symptoms than are those without AE (68% vs 27%, $p = 0.001$); this finding is also similar to our previous study. Although they do not describe the site of AE and all patients with CholU in our study were Japanese, it is presumed that the racial difference is not large.

2.2.4 CholU-Anhd

CholU with anhidrosis and/or hypohidrosis is a subtype of CholU that is associated with depressed perspiration, which ranges from anhidrosis to hypohidrosis [40, 41]. This subtype of CholU has been reported using the term “CholU with anhidrosis and/or hypohidrosis (CholU-Anhd)” [21, 40]. Neurologists have defined AIGA as an acquired impairment in total body sweating despite exposure to heat or exercise without a clear cause. Acquired idiopathic generalized anhidrosis is associated with neither dysautonomia nor any neurological abnormalities except sudomotor dysfunction. Acquired idiopathic generalized anhidrosis is assumed to be associated with three pathological conditions: sudomotor neuropathy, idiopathic pure sudomotor failure, and sweat gland failure [30]; among these conditions, idiopathic pure sudomotor failure accounts for a large proportion of cases of AIGA. Many cases of AIGA are associated with CholU [10]. These pathological conditions are predominant in men and are likely to be complicated by pain and paresthesia; however, psychogenic sweating function is preserved [30].

Our recent comparative study of the subjective symptoms of sweat allergy-type CholU (i.e., conventional sweat allergy-type CholU and CholU-PA) and CholU-Anhd demonstrated that CholU-Anhd was predominant in patients with pain with a negative autologous sweat test or a negative basophil activation test and that sweat allergy-type CholU was predominant in patients with itching [12]. Although the reason is unknown, most cases of AIGA have been reported in Asia, especially in Japan. Regarding the clinical picture of CholU-Anhd, we often encounter patients with a goosebump-like punctate rash with a surrounding erythematous halo as shown in Fig. 1d. A goosebump-like rash without erythema may also appear in patients with CholU-Anhd.

Few epidemiological data on AIGA, including CholU-Anhd, have been published; therefore, the exact prevalence and morbidity of AIGA remain unclear. It is mentioned that patients with AIGA are rare; however, patients with AIGA can be misdiagnosed, and a precise diagnosis may be achieved in only a small proportion of patients because the presence and diagnostic method of AIGA is not well recognized. Over the past 10 years, approximately 50 patients were newly diagnosed with AIGA in our facility (Kobe University) [Fukunaga et al., unpublished data], suggesting that more patients with AIGA might exist. An epidemiological survey in Japan was carried out by a committee comprising members commissioned by the Japanese Dermatological Association, Japan Society of Neurovegetative Research, and Japanese Society for Perspiration Research [30]. In total, 145 cases of AIGA were identified among 94 departments of neurology or dermatology at Japanese university hospitals from 2010 through 2015, although the data are a little old. The incidence was significantly higher in men (126 men and 19 women), as described in a previous report. As a new finding, in Japan under the coronavirus disease (COVID-19) 2019 pandemic, the number of patients is increasing further as a sense of daily medical care level and by expert opinion. An elevated serum carcinoembryonic antigen level might be a marker of disease activity of AIGA [42].
2.3 Pathophysiology

Although a considerable number of studies have been conducted, the pathomechanisms underlying ChoU remain to be elucidated. As mentioned above, it is highly possible that the small number of studies that distinguish among the subtypes of ChoU is likely to be related to the delay in elucidating the pathophysiology of ChoU. Even in such situations, several factors are known to be involved in the pathological condition of ChoU, including histamine, cholinergic-related substances, sweat allergy, serum factors, poral occlusion, leakage of sweat in the dermis, and hypohidrosis/anhidrosis. Below, we summarize which of these factors are most closely related to each subtype.

2.3.1 Histamine

Quite old studies have demonstrated that the serum histamine level increases during the development of symptoms and after exercise in patients with ChoU [43, 44]. Classic histamine receptor antagonists have been proposed as useful, but they are often insufficient in severe cases of ChoU. One study showed that administration of ketotifen was clinically effective in all four patients with ChoU refractory to conventional classic antihistamine therapy and that the release of mast cell mediators (such as histamine) in the blood was blocked after exercise challenge [45]. At present, second-generation non-sedating histamine H1 receptor antagonists (H1RAs) are recommended as the first-line therapy in patients with ChoU; however, compared to patients with other types of urticaria, some patients with ChoU do not respond to standard H1RA therapy [6, 8, 46]. Our previous study found that the addition of the histamine H2 receptor antagonist lafutidine to H1RA therapy in patients with refractory ChoU that was unresponsive to up-dosing of H1RA reduced the severity of itching, the frequency of whealing, and the size of the wheals [8]. Histamine H1 receptor antagonist up-dosing at four-fold in 32 patients with ChoU refractory to standard H1RA therapy substantially improves the disease activity of ChoU in fewer than half of all patients [46]. These findings suggest that histamine plays a fairly important role in the development of ChoU but that additional mediators other than histamine may also be closely associated with the development of ChoU. However, the above-mentioned studies did not examine or mention the subtype of ChoU. Although H1RA therapy is recommended for ChoU-Anhd, which corresponds to AIGA and idiopathic pure sudomotor failure [30, 47], the effectiveness of this therapy has not yet been studied in a randomized trial. In our experience, H1RA therapy is less effective in ChoU-Anhd than in sweat allergy-type ChoU, suggesting a lower involvement of histamine in the pathophysiology of ChoU-Anhd. Further study of this topic is required.

2.3.2 Sweat Allergy

The concept of hypersensitivity to human sweat was first described in 1953 [48]. The issue of sweat allergy was not spotlighted again until 1989, when Adachi and Aoki [49] performed a radioallergosorbent test and detected an IgE antibody to sweat in patients with atopic dermatitis. This immediate-type allergic reaction to sweat was also confirmed in patients with ChoU in 1994 [31]. That study also demonstrated that after transfer of the patient’s serum into a normal subject, the ASwST showed positive results, indicating that these patients with ChoU have a type I allergy to their own sweat. Hide et al. observed that basophils of patients with atopic dermatitis released histamine when mixed with sweat, and this reaction was inhibited by the removal of IgE from the basophils in 2002 [50]. Furthermore, we found in 2005 that 11 of 17 patients with ChoU showed immediate-type skin reactions and confirmed that the level of histamine release from basophils in the response to autologous sweat was well correlated with response of the ASwST [24]. Taka-hagi et al. found that patients with ChoU exhibited histamine release from basophils in response to semi-purified sweat antigen, which induced histamine release from mast cells and basophils via antigen-specific IgE in patients with atopic dermatitis, in 2009. Hiragun et al. [33] identified a putative protein, MGL_1304 of Malassezia globosa, as a major allergen in the sweat of humans with atopic dermatitis in 2013 and ChoU in 2014 as described earlier in Sect. 2.2.1 [34]. These findings suggest that MGL_1304 in sweat is a major antigen for many patients with ChoU who have a sweat allergy. We speculate that many of the patients with ChoU enrolled in the above study had sweat allergy-type ChoU, but whether the study included patients with the ChoU-Anhd subtype is unclear. In contrast, we recently used this commercial histamine release test with semi-purified sweat antigen to detect a sweat allergy in a characteristic case series of patients with ChoU-PA [17]. In that study, we found a positive correlation between IgE-radioallergosorbent test titers against Malassezia species and the histamine release test with the semi-purified sweat antigen. Moreover, we demonstrated that the basophil activation test using the semi-purified sweat antigen displayed a higher sensitivity and negative predictive value and a lower number of non-responders than did the histamine release test in 47 patients (including 41 patients with ChoU) whose symptoms worsened with sweating [35]. Our previous study revealed that only two of eight patients with AIGA had a sweat allergy detected by the histamine release test on sweat or the skin test using autologous sweat, suggesting that a sweat allergy is not involved in the pathogenesis of AIGA [10].
2.3.3 Cholinergic-Related Substances

The sweat glands receive sympathetic innervation but express CHRM3, which is normally expressed in the parasympathetic nervous system. Acetylcholine induces sweating when injected intradermally, causing pinpoint wheals around the injection site (Fig. 2, left side) [24]. This is called the ACh test and is used as an adjunct diagnostic technique for CholU. The ACh test can also be used as a local sweating test when used in combination with the Minor method (Fig. 2, right side) [24]. In fact, recent European reports have shown that ACh injections elicit a wheal and flare in more than one-third of patients with CholU, although the subtype of CholU is unknown [22]. In our previous study, six (50%) of the 12 patients with CholU tested showed a positive response in the ACh test, and all six patients who developed satellite wheals after the ACh test showed hypersensitivity to sweat [24]. It is important to note that the positive ACh test result in this study reflected the appearance of the surrounding satellite wheal, not the injection site. Furthermore, the surrounding satellite wheal is known to coincide with the sweating point [24]. In other words, the positive ACh test result, which reflects the wheal of the surrounding satellites, indicates that ACh promotes sweating from the secretory part of the sweat glands via CHRM3. It is highly possible that the positive ACh test result reflects the generated sweat leaks from the sweat duct to the dermis and degranulation of mast cells via a sweat allergy around the sweat ducts. It has been reported that in atopic dermatitis, which is easily associated with CholU, sweat leaks into the dermis because of decreased expression of claudin-3 in the sweat ducts in the dermis [51].

In contrast, the CholU-Anhd subtype tends to be less frequently associated with the formation of satellite wheals after the ACh test (Fukunaga A, et al., unpublished data). Sawada et al. [9] also reported that the ACh injection induces no reaction at the anhidrotic site in patients with the CholU-Anhd subtype. The authors found that not only sweat glands but also mast cells express CHRM3. A schematic was proposed in which ACh released from postganglionic sympathetic nerves cannot be trapped by the ACh receptors of eccrine glands because of decreased expression of these receptors and overflow of ACh to adjacent mast cells secondary to decreased expression of ACh esterase in the CholU-Anhd subtype [9, 25]. Based on their series of studies, Tokura classified CholU into the ACh-direct sweat allergic type and the ACh-indirect depressed sweat type from the aspect of ACh involvement [52]. Thus, ACh and other cholinergic-related substances appear to play an important role in the development of CholU. However, we believe that further research is needed to determine the involvement of these substances in each subtype of CholU.

2.3.4 Poral (Acrosyringium) Occlusion

Several reports have suggested that CholU is caused by poral occlusion. Kobayashi et al. [53] documented that biopsy specimens from two patients with CholU and hypohidrosis showed occlusion of the superficial acrosyringium. Rho [54] reported that patients with CholU, most of whom develop symptoms only in the winter season, have a relatively high complication rate of hypohidrosis and that topical application of antikeratolytic agents to the affected area may be helpful. These reports suggest that poral occlusion is also involved in the etiology of CholU accompanied by hypohidrosis. We also reported a patient with AIGA accompanied by CholU whose histopathology showed occlusion of the superficial acrosyringium [55]. Moreover, firm keratotic plugs suggesting poral occlusion were observed in a patient with acquired idiopathic partial anhidrosis, and the application of adapalene gel (which is reportedly effective for a reduction in keratotic plugs in patients with porokeratosis) improved sweating function within 3 weeks [56]. Based on these reports, whether poral occlusion is the cause of the CholU-Anhd subtype or the result of decreased sweating remains unclear.

2.3.5 Hypohidrosis/Anhidrosis

The various etiologies of decreased sweating in patients with CholU include autoimmunity to sweat glands or ACh receptors, degeneration of post-ganglionic sympathetic skin nerve fibers, and poral occlusion [26, 40, 53, 57, 58]. In contrast,
there is little information about the pathomechanism by which CholU occurs in the CholU-Anhd subtype (i.e., AIGA accompanied by CholU). As explained in the above section on cholinergic-related substances, Sawada et al. [9, 25] proposed that ACh cannot be trapped by the ACh receptors of eccrine glands because of decreased expression of these receptors and decreased expression of ACh esterase in the CholU-Anhd subtype, and overflow of ACh acts on adjacent mast cells to form CholU. Indeed, research has shown that mast cells express CHRM3 [9]. In contrast, whether ACh can induce degradation of human mast cells in vivo remains unclear. The clinical picture of CholU associated with hypohidrosis may be a goosebump-like punctate rash either with or without an erythematous halo (Fig. 1d), and further research is required to elucidate the pathophysiology of the CholU-Anhd subtype. A recent study showed that an elevated serum carcinoembryonic antigen level might be a marker of disease activity of AIGA [59]. The herein-described categorization and pathophysiological features of each subtype of CholU are illustrated in Table 1 and Fig. 3.

### 3 Disease Burden of CholU

Specific tools for CholU had been missing until the recent development of the first disease-specific, health-related quality-of-life instrument for CholU: the Cholinergic Urticaria Quality of Life Questionnaire (CholU-QoL) [11]. This report described correlations between the CholU-QoL scores, the Dermatology Life Quality Index scores, and urticaria control test scores. Moreover, it showed that the domain “emotions” of CholU-QoL scores was most strongly affected in patients with CholU [11], although the subtype of CholU was not mentioned. Our previous study also did not focus on the subtypes of CholU, but it showed that the total Dermatology Life Quality Index score was 10.1 ± 5.5 and that patients with refractory CholU unresponsive to H1RA had quite an impaired quality of life [8]. Munetsugu et al. [60] reported that the Dermatology Life Quality Index impairment in patients with AIGA was equivalent to or more severe than that in patients with atopic dermatitis. Steroid pulse therapy alleviated the anhidrosis of all eight patients with AIGA.

### Table 1 Subtype categorization and pathophysiological features of CholU

| Subtype                  | Histamine | Sweat allergy | Cholinergic-related substances | Autologous serum skin test | Sex predominance | Atopic predisposition | Hypohidrosis | Pathology | Severity (author’s opinion) |
|--------------------------|-----------|---------------|--------------------------------|---------------------------|------------------|-----------------------|--------------|-----------|-----------------------------|
| Conventional sweat allergy-type CholU | Deeply involved | Positive | Acetylcholine test: positive | Negative | None | ND | None | Sweat allergy, sweat leaking | Moderate |
| Follicular-type CholU    | Involved  | Negative | Acetylcholine test: negative | Positive | None | ND | ND | Serum factor | Mild |
| CholU-PA                 | Deeply involved | Positive | ND | Negative | Female | Strong | None | Sweat allergy, pre-existence of eczema | Severe |
| CholU-Anhd               | Less involved | Negative | Acetylcholine test: negative | ND | Male | Weak | Always | Excess acetylcholine following decrease of CHRM3 expression on sweat gland, CHRM3 expression on mast cells, poral occlusion, carcinoembryonic antigen | Severe |

CholU cholinergic urticaria, CholU-Anhd cholinergic urticaria with acquired anhidrosis and/or hypohidrosis, CholU-PA cholinergic urticaria with palpebral angioedema, CHRM3 cholinergic/acetylcholine receptor M3, ND not determined

△ Adis
Fig. 3 Pathophysiology of each subtype of cholinergic urticaria (CholU). a Conventional sweat allergy-type CholU (i); follicular-type CholU (ii); and cholinergic urticaria with palpebral angioedema (CholU-PA) (iii). In the sweat allergy type [(i) and (iii)], wheals are formed around sweat glands due to leakage of sweat into the dermis and IgE-mediated reaction of surrounding mast cells. In follicular-type CholU (ii), serum factor and acetylcholine stimulate mast cells around the hair follicles to form wheals consistent with the hair follicles. b CholU with acquired anhidrosis and/or hypohidrosis (iv). In cholinergic urticaria with acquired anhidrosis and/or hypohidrosis (CholU-Anhd), CHRM3 expression (acetylcholine receptor) is decreased in the sweat glands, and acetylcholine overflows to promote degranulation from the adjacent mast cells. There may be infiltration of inflammatory cells such as lymphocytes and mast cells around the sweat glands. Sweat leakage and/or poral occlusion may also be involved. CEA carcinoembryonic antigen.
and the symptomatic improvement was clearly linked to an improved quality of life [10].

4 Diagnosis of CholU

4.1 Provocation Test and Disease Severity/Activity Score

The clinical diagnosis of CholU is usually not difficult, as the symptoms of CholU develop only after an increased body temperature has been stimulated in a repetitive manner and the appearance of the eruption is characteristic. However, a provocation test should be performed to accurately diagnose and rule out other types of urticaria and EIA. Provocation tests for the diagnosis of CholU are performed by raising the body temperature through exercise (treadmill or stationary bicycle) or the use of a hot bath (42 °C for 15 minutes) [6, 61, 62]. The EAACI/GA²LEN/EDF/UNEV consensus panel recommends the following criterion to confirm the diagnosis of CholU: the core body temperature has increased by >1.0 °C over the baseline as indicated by a passive warming test involving sitting for up to 15 min in a bath filled with water at 42 °C [6]. Although the use of an esophageal or rectal thermometer to measure core body temperature is more accurate than the use of an oral thermometer, the former is invasive and unsuitable for outpatients. Therefore, a standardized protocol for diagnosing and measuring CholU thresholds using pulse-controlled ergometry has been proposed [63]. Pulse-controlled incremental ergometry for 30 min (stationary bicycle), increasing their pulse rate by 15 beats every 5 min with an ambient temperature of 20–22 °C, is sensitive and specific for diagnosing CholU. The median time to induce wheals using this technique was 27 min, and four of ten patients with CholU had symptoms after the end of the exercise. This report revealed that sweating itself is more important in the development of CholU than the rise in core body temperature [63]. A foot bath thermal sweating test (43 °C for 30 min, room temperature of approximately 25 °C, relative humidity of 40–50%, and use of the lower leg) is standardly performed in Japan as a systemic sweating test (Fig. 4). A foot bath thermal sweating test may also serve as a whealing provocation test for CholU-Anhd (i.e., AIGA accompanied by CholU).

Assessment scores for disease severity and activity specific to CholU have been developed. The Cholinergic Urticaria Severity Index is used to assess the severity of CholU [63]. The Cholinergic Urticaria Severity Index is a sum score that takes into account the frequency of CholU symptoms, eliciting factors, duration of skin lesions, and itch. Accordingly, the Cholinergic Urticaria Severity Index score ranges from 0 to 21 points: <5 points: very mild CholU; 5–9 points: mild CholU; 10–15 points: moderate CholU; >15 points: severe CholU. The Weekly Cholinergic Urticaria Activity Score (CholUAS7) is used to assess the disease activity of CholU; it is calculated as the 7-day sum of [(wheal day + itch day) × intensity of elicitor day], and the maximum score is 168 points [64].

4.2 Differential Diagnosis

Cholinergic urticaria needs to be differentiated from other types of inducible urticaria and anaphylaxis in terms of clinical episodes and the rash shape (Table 2). Cholinergic urticaria must be differentiated from EIA and heat urticaria based on whether the clinical episode has developed secondary to exercise and/or heat stimulation. Exercise-induced anaphylaxis includes four types: food-independent EIA, food-dependent EIA with IgE sensitivity, food-dependent EIA without IgE sensitivity, and drug-dependent EIA [28]. Strenuous exertion may provoke both EIA and CholU, but passive warming will induce solely CholU and not EIA. The wheals in EIA are typically large, could also be small or even absent, and appear as a diffuse erythematosus change in EIA but the wheals are typically small in CholU. Heat urticaria is a rare type of physical (inducible) urticaria that is characterized by itchy erythema and well-demarcated wheals appearing soon after heat exposure, and the wheals are restricted
to the heated area [65]. Heat urticaria can be differentiated from CholU by the characteristic clinical presentation that develops after the provocation tests [6].

Cholinergic urticaria should be differentiated from aquagenic urticaria and adrenergic urticaria with a similar clinical presentation of a punctate rash. Aquagenic urticaria is a rare form of chronic inducible urticaria in which contact with any source of water, regardless of its temperature or pH, evokes small pruritic wheals surrounded by flares [37, 66]. The diagnosis is based on the clinical history and water provocation test result. In the water provocation test, a compress or towel soaked with 35–37 °C water or physiological saline is placed on the patient’s trunk. Adrenergic urticaria is a rare type of stress-induced physical urticaria characterized by widespread pruritic punctate wheals triggered by stress, trauma, and emotional upset [36]. Adrenergic urticaria can be distinguished from CholU by the presence of a white halo of vasoconstriction surrounding small red or pink wheals [67]. Adrenergic urticaria can be diagnosed by an intradermal injection of adrenaline or noradrenaline, which causes the characteristic rash [68]. A positive noradrenaline test result and negative ACh skin test result can be useful for the differential diagnosis of adrenergic urticaria and CholU, although these test results are not definitive because CholU may result in a negative ACh skin test [68].

Finally, the subjective symptom of CholU is a feeling of stinging or tingling pain and/or itching during sweating. A recent study focusing on dermal pain triggered by sweating stimuli showed that ten of 30 patients with dermal pain triggered by sweating stimuli did not develop eruptions [69]. In other words, as there is a group of patients without eruptions that show subjective symptoms similar to those of CholU, this pathological condition should be differentiated.

### 5 Management of and Therapeutic Approach to CholU

The therapeutic approach to CholU varies greatly based on the presence of sweating dysfunction (CholU-Anhd subtype and other subtypes). Therefore, a differential diagnosis of subtypes based on the presence of a sweating abnormality is very important before treatment. However, few studies have evaluated therapeutic approaches focusing on the subtypes of CholU.

Many patients in studies conducted before the consideration of CholU subtypes showed only a mild-to-moderate response to standard H1RA doses [8, 46, 70]. Increasing the dose of an H1RA in 32 patients with CholU that is refractory to standard doses may improve the disease activity, but this occurs in fewer than half of all patients, although there is no description regarding the CholU subtype [46]. Adding a histamine H2 receptor antagonist was reportedly effective in patients with refractory CholU that was unresponsive to up-dosing of an H1RA, although there is no description regarding the CholU subtype [8]. There are also reports on the efficacy of scopolamine butylbromide (an anticholinergic agent) [71]; combinations of propranolol (a β2-adrenergic blocker), antihistamines, and montelukast [72]; and the injection of botulinum toxin [73]. Although the side-effect profile of danazol limits its use, high doses of danazol (600 mg daily) have been reported to be effective [6]. Several studies have shown that omalizumab is effective for severe CholU cases [74, 75], but cases of omalizumab treatment failure has also been reported [76–78]. Desensitization protocols involving regular physical exercise and/or bathing or treatment with autologous sweat in patients with sweat allergy-type CholU have been reported [19, 20, 79]. A more
recent report showed that regular sweating activity is effective in alleviating the symptoms of CholU with or without hypohidrosis [80].

Regarding the CholU-Anhd subtype, systemic administration of corticosteroids such as intravenous high-dose (500–1000 mg) steroid pulse therapy for AIGA appears to merit recommendations based on the findings presented in numerous case reports despite an insufficient level of research-based evidence [10, 30, 81]. A recent report stated that the treatment response rate of steroid pulse therapy in 57 patients with AIGA was 73%, and the recurrence rate was 48%. Furthermore, it is interesting that the effectiveness was reduced when the steroid pulse therapy was given in the autumn before it became cold [82]. A trial of oral immunosuppressants is worthwhile in patients who do not respond to steroid pulse therapy, although only one case is reported in Japan [30]. In patients with AIGA, H1RAs can be administered at increased doses appropriate to the symptoms experienced [83]. Topical application of keratolytic agents is reportedly effective in treating hypohidrotic CholU, which is associated with the occlusion of sweat ducts [54]. Oral pilocarpine is reportedly effective for alleviation of the symptoms of AIGA [84]. Omalizumab was shown to be effective in a patient with CholU-Anhd with atopic dermatitis [85]. Medications acting on nervous systems transiently attenuate dermal pain triggered by sweating stimuli including CholU-Anhd [69]. Takahagi et al. reported that Ca\textsuperscript{2+} channel α2δ ligands and anti-anxiety agents might be effective for dermal pain (response ratio, 33% and 60%) [69].

Overall, however, the currently available treatments for CholU-Anhd are not satisfactorily effective with the exception of steroid pulse therapy, and symptomatic recurrence often occurs even after steroid pulse therapy. Thus, the development of better treatment methods is expected. These recommended therapeutic management approaches are summarized in Fig. 5.

6 Conclusions

This review focused primarily on the subtypes of CholU. Although many unclear points remain in the pathophysiology of CholU, subtype classification is essential for an accurate understanding of this disease because the pathophysiology of each subtype is likely to be different. In addition, subclassing CholU, which is relatively resistant to conventional treatments and significantly impairs quality of life, leads to the provision of better treatments. In the future, it is expected that the pathophysiology and therapeutic management of CholU will be established with a focus on specific CholU subtypes.

Acknowledgments We thank Angela Morben, DVM, ELS, from Edanz (https://jp.edanz.com/ac), for editing a draft of this manuscript.
Declarations

Funding This work was supported in part by Japan Society for the Promotion of Science KAKENHI (Grant number 20K08651).

Conflicts of interest/competing interests AF has received fees for speaking from Novartis, Sanofi, Takeda, Tanabe-Mitsubishi, Kyowa-Kirin, Kyorin, Kaken, and Taiho. AF has also received funds for sponsored/research from Novartis and Taiho. KW has received fees for speaking from Sanofi, Muroho, Novartis, Taiho, Tanabe-Mitsubishi, Kyowa-Kirin, and AbbVie. YO has received fees for speaking from Janssen Pharm. The other authors have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Consent was obtained from the patient in the presented photograph.

Availability of data and material Not applicable.

Code availability Not applicable.

Author contributions AF had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. YO, SI, MM, and TF drafted the manuscript. KW and TF supervised the conduct of this study. All authors reviewed the manuscript draft and revised it critically for intellectual content. All authors approved the final version of the manuscript to be published.

References

1. Duke WW. Urticaria caused specifically by the action of physical agents. J Am Med Assoc. 1924;83:3–9.
2. Hirschmann JV, Lawlor F, English JS, Louback JB, Winkelmann RK, Greaves MW. Cholinergic urticaria: a clinical and histologic study. Arch Dermatol. 1987;123(4):462–7.
3. Moore-Robinson M, Warin RP. Some clinical aspects of cholinergic urticaria. Br J Dermatol. 1968;80(12):794–9.
4. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAAICI/GA(2)LEN/Euro-GuidDerm/APAAA/CI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021.
5. Zuberbier T, Althaus C, Chantraine-Hess S, Czarnetzki BM. Prevalence of cholinergic urticaria in young adults. J Am Acad Dermatol. 1994;31(6):978–81.
6. Magerl M, Altichter S, Borzova E, Gimenez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias: the EAACI/GA(2)LEN/Euro-GuidDerm/APAAA/CI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021.
7. Fukunaga A. Japanese guidelines for diagnosis and treatment of urticaria 2018. Arerugi. 2019;68(10):1181–7.
8. Hatakeyama M, Fukunaga A, Washio K, Ogura K, Yamada Y, Horikawa T, et al. Addition of lafutidine can improve disease activity and lead to better quality of life in refractory cholinergic urticaria unresponsive to histamine H1 antagonists. J Dermatol Sci. 2016;82(2):137-9.
9. Sawada Y, Nakamura M, Bito T, Fukamachi S, Kabashima R, Sugita K, et al. Cholinergic urticaria: studies on the muscarinic cholinergic receptor M3 in anhidrotic and hypohidrotic skin. J Invest Dermatol. 2010;130(11):2683–6.
10. Fukunaga A, Hatakeyama M, Tsujimoto M, Oda Y, Washio K, Nishigori C. Steroid treatment can improve the impaired quality of life of patients with acquired idiopathic generalized anhidrosis. Br J Dermatol. 2015;172(2):537–8.
11. Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, et al. Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL). Clin Exp Allergy. 2018;48(4):433–44.
12. Mizuno M, Fukunaga A, Washio K, Imamura S, Oda Y, Nishigori C. A visual analogue scale for itch and pain in 23 cases of cholinergic urticaria. J Eur Acad Dermatol Venereol. 2020;34(9):e493–5.
13. Kaplan AP, Gorofalo J. Identification of a new physically induced urticaria: cold-induced cholinergic urticaria. J Allergy Clin Immunol. 1981;68(6):438–41.
14. Lawrence CM, Jorizzo JL, Kobza-Black A, Coutts A, Greaves MW. Cholinergic urticaria with associated angio-oedema. Br J Dermatol. 1981;105(5):543–50.
15. Vadas P, Sinilaita A, Chaim M. Cholinergic urticaria with anaphylaxis: an underrecognized clinical entity. J Allergy Clin Immunol Pract. 2016;4(2):284–91.
16. Mellerowicz EJ, Asady A, Maurer M, Altrichter S. Angioedema frequently occurs in cholinergic urticaria. J Allergy Clin Immunol Pract. 2019;7(4):1355-7.e1.
17. Washio K, Fukunaga A, Onodera M, Hatakeyama M, Taguchi K, Ogura K, et al. Clinical characteristics in cholinergic urticaria with palpebral angiooedema: report of 15 cases. J Dermatol Sci. 2017;85(2):135–7.
18. Oda Y, Fukunaga A, Tsujimoto M, Hatakeyama M, Washio K, Nishigori C. Combined cholinergic urticaria and cold-induced cholinergic urticaria with acquired idiopathic generalized anhidrosis. Allergol Int. 2015;64(2):214–5.
19. Horikawa T, Fukunaga A, Nishigori C. New concepts of hive formation in cholinergic urticaria. Curr Allergy Asthma Rep. 2009;9(4):273–9.
20. Nakamizo S, Egawa G, Miyachi Y, Kabashima K. Cholinergic urticaria: pathogenesis-based categorization and its treatment options. J Eur Acad Dermatol Venereol. 2012;26(1):114–6.
21. Fukunaga A, Washio K, Hatakeyama M, Oda Y, Ogura K, Horikawa T, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management. Clin Auton Res. 2018;28(1):103–13.
22. Altrichter S, Wang Y, Schumacher P, Alraboni O, Church MK, Maurer M. Acetylcholine-induced whealing in cholinergic urticaria: what does it tell us? J Dermatol Sci. 2021;103(1):10–5.
23. Bito T, Sawada Y, Tokura Y. Pathogenesis of cholinergic urticaria in relation to sweating. Allergol Int. 2012;61(4):539–44.
24. Fukunaga A, Bito T, Tsuru K, Oohashi A, Yu X, Ichihashi M, et al. Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol. 2005;116(2):397–402.
25. Sawada Y, Nakamura M, Bito T, Sakabe J, Kabashima-Kubo R, Hino R, et al. Decreased expression of acetylcholine esterase in cholinergic urticaria with hypohidrosis or anhidrosis. J Invest Dermatol. 2014;134(1):276–9.
26. Nakazato Y, Tamura N, Ohkuma A, Yoshimaru K, Shimazu K, Hino R, et al. Decreased expression of acetylcholine esterase in cholinergic urticaria with acquired idiopathic generalized anhidrosis. Am J Dermatopathol. 2015;37(9):911–8.
27. Okuyama S, Kojo K, Takayama N, Hiragun M, Kan T, Hide M. Case of cholinergic urticaria accompanied by anaphylaxis. J Dermatol. 2017;44(11):1291–4.
28. Geller M. Clinical management of exercise-induced anaphylaxis and cholinergic urticaria. J Allergy Clin Immunol Pract. 2020;8(7):2209–14.

△ Adis
29. Tokura Y. New etiology of cholinergic urticaria. Curt Probl Dermatol. 2016;51:94–100.
30. Munetsugu T, Fujimoto T, Oshima Y, Sano K, Murota H, Satoh T, et al. Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan. J Dermatol. 2016;44:394–400.
31. Adachi J, Aoki T, Yamatodani A. Demonstration of sweat allergy in cholinergic urticaria. J Dermatol Sci. 1994;7(2):142–9.
32. Takahagi S, Tanaka T, Ishii K, Suzuki H, Kameyoshi Y, Shindo H, et al. Sweat antigen induces histamine release from basophils of patients with cholinergic urticaria associated with atopic diathesis. Br J Dermatol. 2009;160(2):426–8.
33. Hiragun T, Ishii K, Hiragun M, Suzuki H, Kan T, Mihaa S, et al. Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J Allergy Clin Immunol. 2013;132(3):608–15.e4.
34. Kato T, Komatsu H, Tagami H. Exercise-induced urticaria and angioedema as a manifestation of cholinergic urticaria. J Allergy Clin Immunol. 1981;68(4):319–24.
35. Kato T, Komatsu H, Tagami H. Exercise-induced urticaria and angioedema: reports of two cases. J Dermatol. 1997;24(3):189–92.
36. Itakura E, Urabe K, Yasumoto S, Nakayama J, Furue M. Cholinergic urticaria: severe extra-cutaneous symptoms following cold water exposure. Allergol Int. 2018;67(2):295–7.
37. Fukumoto T, Ogura K, Fukunaga A, Nishigori C. Aquagenic urticaria: severe extra-cutaneous symptoms following cold water exposure. J Dermatol. 2014;41(1):83–93.
38. Oda Y, Washio K, Fukunaga A, Imamura S, Hatakeyama M, Ogura K, et al. Clinical utility of the basophil activation test in the diagnosis of sweat allergy. Allergol Int. 2020;69(2):261–7.
39. Shelley WB, Shelley ED. Adrenergic urticaria: a new form of stress-induced hives. Lancet. 1985;2(8463):1031–3.
40. Itakura E, Urabe K, Yasumoto S, Nakayama J, Furue M. Cholinergic urticaria successfully treated with ketotifen. J Allergy Clin Immunol. 1980;66(5):358–65.
41. Kaplan AP, Natbony SF, Tawil AP, Fruchtler L, Foster M. Exercise-induced anaphylaxis as a manifestation of cholinergic urticaria. J Allergy Clin Immunol. 1975;55(6):394–402.
42. Soter NA, Wasserman SI. Physical urticaria/angioedema: an experimental model of mast cell activation in humans. J Allergy Clin Immunol. 1980;65(5):358–65.
43. Mclean SP, Arreaza EE, Lett-Brown MA, Grant JA. Refractory cholinergic urticaria successfully treated with ketotifen. J Allergy Clin Immunol. 1989;83(4):738–41.
44. Koch K, Wellner K, Werner A, Maurer M, Altrichter S. Anti-histamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. J Clin Immunol. 2016;35(5):1483–5.e9.
45. Young AT, Yedidi RS, Raffi J, McCallmont TH, North J, Brinker A, et al. Idiopathic pure sudomotor failure: a review and two cases. Int J Womens Dermatol. 2021;7(3):276–9.
46. Sulzberger MB, Harrmann F, Borota A, Strauss MB. Studies of sweating. VI. On the urchinogenic properties of human sweat. J Invest Dermatol. 1953;21(5):293–303.
47. Adachi K, Aoki T. IgE antibody to sweat in atopic dermatitis. Acta Derm Venerol Suppl (Stockh). 1989;144:83–7.
48. Hide M, Tanaka T, Yamamura Y, Koro O, Yamamoto S. IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm Venerol. 2002;82(5):335–40.
71. Tsunemi Y, Ihn H, Saeki H, Tamaki K. Cholinergic urticaria successfully treated with scopolamine butylbromide. Int J Dermatol. 2003;42(10):850.
72. Feinberg JH, Toner CB. Successful treatment of disabling cholinergic urticaria. Mil Med. 2008;173(2):217–20.
73. Sheraz A, Halpern S. Cholinergic urticaria responding to botulinum toxin injection for axillary hyperhidrosis. Br J Dermatol. 2013;168(6):1369–70.
74. Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150(3):288–90.
75. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63(2):247–9.
76. Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol. 2009. https://doi.org/10.3109/03068258.2009.1069521.
77. Altrichter S, Chuamanochan M, Knoth H, Asady A, Ohanyan T, Metz M, et al. Real-life treatment of cholinergic urticaria with omalizumab. J Allergy Clin Immunol. 2019;143(2):788–91.e8.
78. Kim JH, Park HS, Ye YM, Shin YS, Kang HR, Chung SJ, et al. Omalizumab treatment in patients with cholinergic urticaria: a real-world retrospective study in Korea. Allergy Asthma Immunol Res. 2020;12(5):894–6.
79. Kozaru T, Fukunaga A, Taguchi K, Ogura K, Nagano T, Oka M, et al. Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int. 2011;60(3):277–81.
80. Minowa T, Sumikawa Y, Kan Y, Kamiya T, Ubara H. Regular sweating activities for the treatment of cholinergic urticaria with or without acquired idiopathic generalized anhidrosis. Dermatol Ther. 2020;33(4):e13647.
81. Ohshima Y, Yanagishita T, Ito K, Tamada Y, Nishimura N, Inukai Y, et al. Treatment of patients with acquired idiopathic generalized anhidrosis. Br J Dermatol. 2013;168(2):430–2.
82. Iida T, Nakamura M, Inazawa M, Munetsugu T, Nishida M, Fujimoto T, et al. Prognosis after steroid pulse therapy and seasonal effect in acquired idiopathic generalized anhidrosis. J Dermatol. 2021;48(3):271–8.
83. Suma A, Murota H, Kitaba S, Yamaoka T, Kato K, Matsui S, et al. Idiopathic pure sudomotor failure responding to oral antihistamine with sweating activities. Acta Derm Venereol. 2014;94(6):723–4.
84. Kubota N, Furuta JI, Onizawa S, Saito A, Nakamura Y, Ishitsuka Y, et al. Oral pilocarpine alleviates the symptoms of acquired idiopathic generalised anhidrosis. Eur J Dermatol. 2019;29(4):422–3.
85. Ihibashi-Kunimi Y, Imafuku S. Cholinergic urticaria with hypohidrosis successfully treated with omalizumab. J Dermatol. 2020;47(2):e47–8.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.